PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. J Natl Cancer Inst. 2021 11 29; 113(12):1733-1743.

View in: PubMed

subject areas

B7-H1 Antigen
Biomarkers, Tumor
Humans
Immunohistochemistry
Triple Negative Breast Neoplasms

authors with profiles

Luciana Molinero